94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Xiaoshan Zhou1,2
Haoran Dai3
Hanxue Jiang2
Hongliang Rui2,4
Wenbin Liu5
Zhaocheng Dong1
Na Zhang6
Qihan Zhao2,6
Zhendong Feng7
Yuehong Hu2,6Fanyu Hou8
Yang Zheng2*
Baoli Liu2*- 1Beijing University of Chinese Medicine, Beijing, China
- 2Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China
- 3Shunyi Branch, Beijing Hospital of Traditional Chinese Medicine, Beijing, China
- 4Beijing Institute of Chinese Medicine, Beijing, China
- 5School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China
- 6School of Traditional Chinese Medicine, Capital Medical University, Beijing, China
- 7Pinggu Hospital, Beijing Hospital of Traditional Chinese Medicine, Beijing, China
- 8School of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China
A Corrigendum on
MicroRNAs: Potential mediators between particulate matter 2.5 and Th17/Treg immune disorder in primary membranous nephropathy
by Zhou X, Dai H, Jiang H, Rui H, Liu W, Dong Z, Zhang N, Zhao Q, Feng Z, Hu Y, Hou F, Zheng Y, Liu B (2022). Front Pharmacol. 13:968256. doi: 10.3389/fphar.2022.968256
In the published article, there was an error in Affiliations [1, 2]. Instead of “1Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China, 2School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China,” it should be “1Beijing University of Chinese Medicine, Beijing, China, 2Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.”
In the published article, there was an error in the Funding statement. The number of the first fund was incorrect. The correct Funding statement appears below.
Funding
This work is supported by grants from Capital’s Funds for Health Improvement and Research (No. 2020-2-2234 to BL), the National Key Research and Development Project of China (No. 2019YFC1709402 to BL), the General project of the National Natural Science Foundation of China (No. 81973793 to BL), and Youth Foundation of National Natural Science Foundation of China (No. 82004269 to HD).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: PM2.5, PLA2R1, microRNA, Th17/Treg, primary membranous nephropathy (PMN)
Citation: Zhou X, Dai H, Jiang H, Rui H, Liu W, Dong Z, Zhang N, Zhao Q, Feng Z, Hu Y, Hou F, Zheng Y and Liu B (2023) Corrigendum: MicroRNAs: Potential mediators between particulate matter 2.5 and Th17/Treg immune disorder in primary membranous nephropathy. Front. Pharmacol. 14:1166591. doi: 10.3389/fphar.2023.1166591
Received: 15 February 2023; Accepted: 16 February 2023;
Published: 27 February 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Zhou, Dai, Jiang, Rui, Liu, Dong, Zhang, Zhao, Feng, Hu, Hou, Zheng and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yang Zheng, MTU0MjAyNTM2QHFxLmNvbQ==; Baoli Liu, bGl1YmFvbGlAYmp6aG9uZ3lpLmNvbQ==